clinical trial · NCT07467564
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Atopic DermatitisDupilumab
brief summary
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
started
Feb 24, 2026
primary completion
May 24, 2027
completion
May 24, 2027
last updated
May 14, 2026
official title
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol